ATNF 180 Life Sciences Corp. Stock Quote

ATNF [NASD]

Index	-	P/E	-	EPS (ttm)	-1.97	Insider Own	17.50%	Shs Outstand	24.13M	Perf Week	-8.99%
Market Cap	246.85M	Forward P/E	-	EPS next Y	-	Insider Trans	-1.04%	Shs Float	13.80M	Perf Month	27.24%
Income	-9.30M	PEG	-	EPS next Q	-	Inst Own	7.30%	Short Float	15.81%	Perf Quarter	62.64%
Sales	-	P/S	-	EPS this Y	-130.90%	Inst Trans	12.74%	Short Ratio	0.90	Perf Half Y	310.84%
Book/sh	0.91	P/B	11.24	EPS next Y	-	ROA	-76.60%	Target Price	-	Perf Year	-3.13%
Cash/sh	0.02	P/C	493.70	EPS next 5Y	-	ROE	-156.80%	52W Range	1.90 - 13.05	Perf YTD	274.73%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-21.58%	Beta	-0.50
Dividend %	-	Quick Ratio	0.10	Sales past 5Y	-	Gross Margin	-	52W Low	438.42%	ATR	0.78
Employees	2	Current Ratio	0.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	57.76	Volatility	7.47% 7.81%
Optionable	Yes	Debt/Eq	0.55	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.10	Prev Close	10.15
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	2.42M	Price	10.23
Recom	-	SMA20	13.73%	SMA50	13.14%	SMA200	48.53%	Volume	251,484	Change	0.79%

Jun-10-21 09:12AM	180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors GlobeNewswire
Jun-01-21 08:00AM	180 Life Sciences Corp. to Present at LD Micro Invitational XI GlobeNewswire +8.90%
May-28-21 08:00AM	180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors GlobeNewswire +7.96%
May-21-21 04:45PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Quarterly Report on Form 10-Q GlobeNewswire +10.61%
Apr-20-21 08:00AM	180 Life Sciences Corp. Announces Collection of All Patient Data for Phase 2b Dupuytrens Disease Trial GlobeNewswire
Apr-19-21 05:00PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Annual Report on Form 10-K GlobeNewswire -16.53%
Apr-14-21 08:15AM	180 Life Sciences Corp. Congratulates Dr. Lynn Williams on International Dupuytren Award 2021 GlobeNewswire
Mar-26-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics GlobeNewswire +18.57%
Mar-25-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters GlobeNewswire +13.65%
Mar-24-21 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders GlobeNewswire
Mar-08-21 01:30PM	180 Life Sciences Corp. to Present at Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC GlobeNewswire +5.46%
Feb-24-21 04:00PM	180 Life Sciences Corp. Announces Closing of $11.7 Million Private Placement GlobeNewswire +11.06%
Feb-19-21 09:00AM	180 Life Sciences Corp. Announces $11.7 Million Private Placement GlobeNewswire -13.46%
Feb-17-21 12:00AM	Do Insiders Own Lots Of Shares In 180 Life Sciences Corp. (NASDAQ:ATNF)? Simply Wall St. -5.45%
Jan-11-21 08:00AM	180 Life Sciences Corp. to Present at the Biotech Showcase(TM) Digital 2021 Conference Newsfile +5.06%
Jan-05-21 02:50PM	180 Life Sciences Corp. to Present at the H.C. Wainwright Bioconnect 2021 Conference GlobeNewswire +7.17%
Dec-03-20 11:08AM	180 Life Sciences Corp. to Present at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15th at 1:40 PM EST GlobeNewswire
Nov-24-20 10:00AM	180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November 27, 2020 GlobeNewswire -6.93%
Nov-23-20 08:30AM	180 Life Sciences Corp. Continues to Expand Intellectual Property Portfolio With Additional Patent Grants GlobeNewswire +17.44%
Nov-17-20 08:00AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders GlobeNewswire
Nov-10-20 11:46AM	180 Life Sciences Announces Completion of Transaction with KBLM Merger Corp IV GlobeNewswire -6.47%

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KRAUSS MARLENE	10% Owner	Dec 17	Sale	2.48	16,506	40,880	2,006,858	Dec 17 05:29 PM
KRAUSS MARLENE	10% Owner	Dec 15	Sale	2.40	17,877	42,905	2,543,676	Dec 17 05:29 PM
KRAUSS MARLENE	10% Owner	Dec 14	Sale	2.45	10,000	24,500	2,561,553	Dec 17 05:29 PM
KRAUSS MARLENE	10% Owner	Nov 25	Sale	2.78	12,182	33,809	2,571,556	Dec 01 07:00 PM
KRAUSS MARLENE	10% Owner	Nov 23	Sale	3.26	60,633	197,676	2,583,738	Dec 01 07:00 PM
KRAUSS MARLENE	10% Owner	Nov 19	Sale	2.12	33,445	70,837	2,644,371	Dec 01 07:00 PM
KRAUSS MARLENE	10% Owner	Nov 18	Sale	2.31	6,700	15,480	2,677,816	Dec 01 07:00 PM
KRAUSS MARLENE	10% Owner	Nov 17	Sale	2.26	3,300	7,445	2,684,516	Dec 01 07:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience